Case Report: A successful rechallenge with aumolertinib after osimertinib-induced severe interstitial lung disease

BackgroundOsimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), demonstrates significant efficacy in treating non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutations. However, EGFR-TKI-induced interstitial lung disease (ILD) is a recog...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hejing Bao, Caijiu Deng, Xi Luo, Haoran Su, Hehong Bao, Jiazhu Hu, Xiaolong Cao, Liping Lin
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-04-01
coleção:	Frontiers in Pharmacology
Assuntos:	aumolertinib EGFR-TKI interstitial lung disease non-small cell lung cancer osimertinib
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1785616/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!